- Prescient Therapeutics onboarded globally renowned cancer and CAR-T specialist Professor Phillip Darcy to its Scientific Advisory Board.
- Professor Darcy is a senior research fellow at NHMRC and group leader of cancer immunotherapy at the Peter MacCallum Cancer Centre in Melbourne.
- Prescient believes that Professor Darcy’s contribution to the company’s shared goal of developing personalised cancer treatment available to more patients will be profound.
Australia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed globally renowned cancer and Chimeric Antigen Receptor-T (CAR-T) expert, Professor Phillip Darcy of Peter MacCallum Cancer Centre, to its Scientific Advisory Board.
Prescient Therapeutics Limited
ASX-listed clinical-stage biotech company Prescient Therapeutics is engaged in developing personalised treatment approaches to treat cancers having unmet or poorly met clinical needs. The company offers targeted as well as cell therapies for several cancers. The cell therapy of PTX comprise of OmniCAR platform and targeted therapies comprise of two drug compounds PTX-200 and PTX-100.
Moreover, for cell therapy approaches, PTX has several other initiatives in progress.
Globally Recognised Professor Phillip Darcy Joins Prescient’s Scientific Advisory Board
On 7 August 2020, Prescient Therapeutics disclosed the appointment of Professor Phillip Darcy, who is an acknowledged leader in the development of new CAR-T cell therapies for cancer, to the Scientific Advisory Board of the company.
In CAR-T cell therapy, patient’s T-cells are used, which are key blood cells safeguarding the body from any infection or disease and reprograms them into a personalised treatment that can identify as well as destroy cancer cells.
Professor Darcy is currently a senior research fellow at NHMRC (National Health and Medical Research Council) and group leader of cancer immunotherapy at the Peter MacCallum Cancer Centre in Melbourne.
Professor Phillip Darcy stated that Prescient is pursuing several promising cell therapy approaches, including cell therapy enhancements, with potential to substantially expand and improve current approaches to CAR-T therapy.
He also added-
Professor Darcy’s work is focused on developing T cell-based immunotherapy approaches for cancer treatments for patients. Currently, Prof Darcy is focused on developing gene-modified mouse and human T-cells expressing CARs that target and eradicate cancer in mice.
Moreover, his work added to the first CAR-T clinical trial in AML (acute myeloid leukaemia) conducted in Australia, which lately declared successful Phase 1 completion. Also, a new study by applying the same technique in lung cancer patients is underway.
Prof Darcy’s work is also focused on the development of combined immune-based therapies for cancer.
Prescient is progressing with a rapid pace in its immunotherapy platform of developing treatments for challenging cancers and appointment of Professor Phillip Darcy would further solidify upcoming prospects of Prescient in the arena of CAR-T.
On 7 August 2020, PTX quoted at A$0.057 (at AEST 1:42 PM) with a market cap of ~A$22.87 million.
To know more about Prescient Therapeutics Limited, click here.
To stay updated with PTX company activities and announcements, please update your details on their investor centre.